Quick answer
Intermediate-risk prostate cancer has ISUP grade group 2 or 3 on biopsy (Gleason 7) or a PSA between 10 and 20 ng/mL, with the tumor confined to the prostate.1 The European guideline accepts radical prostatectomy and radiotherapy with 4 to 6 months of hormone therapy, and allows active surveillance only in carefully selected ISUP 2 cases.2 When I recommend surgery, I advise operating as soon as possible, without hormone therapy while waiting, preserving the nerves whenever possible.
What intermediate risk means
The European guideline groups prostate cancer by risk using the biopsy ISUP grade group, the PSA and the rectal exam:1
| Group | How it is defined |
|---|---|
| Low risk | ISUP 1, PSA below 10 ng/mL and tumor confined to the prostate on the rectal exam |
| Intermediate risk | ISUP 2 or 3, or PSA between 10 and 20 ng/mL, with tumor confined to the prostate on the rectal exam |
| High risk | ISUP 4 or 5, or PSA above 20 ng/mL |
ISUP 2 corresponds to Gleason 3+4, and ISUP 3 to Gleason 4+3. Both add up to 7, but in 4+3 the more aggressive pattern predominates. The page on Gleason and ISUP explains these numbers, and the page on high-risk cancer covers the next group.
Favorable or unfavorable
Intermediate risk covers very different tumors. The American NCCN guideline splits this group in two, based on a 2013 study of 1,024 men treated with radiotherapy.3,4 The intermediate-risk factors are a larger tumor on the rectal exam (cT2b or cT2c), a PSA between 10 and 20 ng/mL and ISUP grade group 2 or 3.
| Item | Favorable | Unfavorable |
|---|---|---|
| Intermediate-risk factors | Only one | Two or three |
| Biopsy grade | ISUP 1 or 2 | ISUP 3 |
| Cores with cancer | Fewer than half | Half or more |
A single item in the right-hand column makes the case unfavorable. In the 2013 study, the unfavorable group had more PSA recurrence, more metastases and more cancer deaths than the favorable group.3 The 2026 European guideline now also splits intermediate risk into favorable and unfavorable, using only PSA and ISUP grade, always with the tumor confined to the prostate on rectal exam:1
- Favorable: ISUP 2 with PSA below 10 ng/mL, or ISUP 1 with PSA 10 to 20 ng/mL.
- Unfavorable: ISUP 2 with PSA 10 to 20 ng/mL, or ISUP 3.
It uses this split to choose some types of radiotherapy.2 The risk group calculator does this with your numbers.
When monitoring is possible
Active surveillance is the standard approach for low-risk cancer. For intermediate risk, the European guideline accepts it in carefully selected ISUP 2 cases:2
- Low disease extent on biopsy and MRI, with less than 10% pattern 4
- PSA below 10 ng/mL and a low PSA density
- A small tumor on the rectal exam (up to cT2a) and few cores with cancer
- A repeat biopsy 6 to 12 months later, to rule out sampling error
The guideline makes clear that this path accepts a higher risk of metastasis. ISUP 3 and tumors with cribriform pattern or intraductal carcinoma on the report are excluded from surveillance.2
I personally do not recommend active surveillance for intermediate risk, including favorable intermediate risk. In these cases, we talk about surgery and radiotherapy.
The numbers help explain why. In a Canadian cohort, metastasis-free survival at 15 years was 95% for low risk and 82% for intermediate risk. It was 84% for Gleason 3+4 tumors and 63% for 4+3.5
Surgery or radiotherapy
When treatment is indicated, the European guideline accepts both paths:2
| Treatment | What the European guideline recommends |
|---|---|
| Radical prostatectomy | Offer to men with a life expectancy above 10 years, preserving the nerves when the risk that the tumor has spread outside the prostate on that side is low |
| External radiotherapy | With 4 to 6 months of hormone therapy. In selected favorable intermediate-risk cases, hormone therapy may not be needed |
| Brachytherapy | Alone, for favorable intermediate risk in men with good urinary function. As a boost to external radiotherapy, for unfavorable risk |
The benefit of short-term hormone therapy with radiotherapy came from trials such as RTOG 94-08, with 1,979 men. Adding 4 months of hormone therapy reduced mortality, and the gain was seen mainly in intermediate-risk men.9
The European guideline recommends focal therapies only within trials or registries.2 The surgery or radiotherapy page compares the side effects of each on urine, erections and the bowel, and focal therapy has its own page.
What the trials show
Three randomized trials compared surgery with observation or monitoring. The European guideline advises that patients know about the first two before deciding:2
- SPCG-4 (Scandinavia): 695 men with clinically detected cancer, randomized to prostatectomy or observation from 1989 to 1999. Surgery reduced cancer death by 11.7 percentage points, with 2.9 years of life gained on average.7
- PIVOT (United States): 731 men randomized to prostatectomy or observation. Across the whole group, the difference in mortality was not significant. In men with intermediate-risk disease, in a subgroup analysis, surgery may have reduced overall mortality by 14.5 percentage points.8
- ProtecT (United Kingdom): 1,643 men randomized to monitoring, surgery or radiotherapy and followed for 15 years. Cancer death was low in all three groups, but metastases were about twice as common with monitoring as with surgery or radiotherapy.6
In ProtecT, more than a third of the men had intermediate- or high-risk disease, and the effect on cancer death did not change with baseline risk. The authors concluded that the choice of treatment weighs benefits against the side effects of each.6 For intermediate risk, the European guideline reserves surveillance for carefully selected ISUP 2 cases.2
How the surgery is done
Robotic radical prostatectomy removes the prostate and seminal vesicles through small incisions. For intermediate-risk cancer, a few points shape the plan:
- Erection nerves: the European guideline advises preserving them when the risk that the tumor has spread outside the prostate on that side is low.2 I preserve the nerves whenever possible.
- Lymph nodes: removing them depends on the chance that the cancer has reached them. In a series of 6,883 intermediate-risk patients cited by the European guideline, that chance was 2.9%.2 I use the 2019 Briganti nomogram, with a 7% cutoff.11 When I remove the lymph nodes, the dissection is always extended. The page on lymph node dissection explains how it is done.
- Robotic approach: compared with open surgery, robotic surgery had less bleeding, fewer transfusions, shorter hospital stays and fewer complications, and continence and erections returned sooner.12,13 Compared with laparoscopy, continence returned sooner and erections were better in men with good erections beforehand.14 In the randomized trial from the University of São Paulo, cancer control was similar with the robot and with open surgery.12 I compare the three in robotic, laparoscopic or open.
In my practice, the hospital stay is 1 to 2 days (discharge usually happens within 24 hours), and the catheter stays in for 7 to 10 days. Work and driving resume after 2 weeks, and sex and heavy activity after 1 month.
How long to wait
A 2021 systematic review pooled 19 studies of men with intermediate- and high-risk disease. Waiting around 3 months generally did not worsen the pathology of the removed prostate, PSA recurrence or survival.10
In my practice, when surgery is recommended for intermediate-risk disease, I advise operating as soon as possible. These numbers allow time to complete tests and preparation calmly, without delaying surgery for no reason. While you wait, hormone therapy is not indicated: the European guideline states that hormone therapy before prostatectomy is not indicated.2
How I approach it
At the consultation, I review the biopsy, PSA, rectal exam and MRI and explain whether your case is favorable or unfavorable. We talk about surgery and radiotherapy, what each offers and how it may affect urine and erections.
I have performed robotic radical prostatectomy since 2020. I have a PhD from the University of São Paulo Medical School and have performed more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. I operate with the robot because, in the studies, the robotic approach brings together the most advantages.
If you already have a diagnosis and want another assessment, a second opinion can be done entirely online, in English, with your test results sent in advance.
Send your case
If you have been diagnosed with intermediate-risk cancer and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
What is intermediate-risk prostate cancer?+
In the European guideline, it is cancer with ISUP grade group 2 or 3 on biopsy (Gleason 3+4 or 4+3) or a PSA between 10 and 20 ng/mL, with the tumor confined to the prostate on the rectal exam.1
What is the difference between favorable and unfavorable intermediate risk?+
The American NCCN guideline splits intermediate risk into two groups. Favorable has a single intermediate-risk factor, ISUP 1 or 2 and fewer than half of the biopsy cores with cancer. Unfavorable has ISUP 3, two or three risk factors, or half or more of the cores with cancer.3,4 In the study that created this split, the unfavorable group had more metastases and more cancer deaths.3 The 2026 European guideline also splits the group, using only PSA and ISUP grade: favorable is ISUP 2 with PSA below 10 ng/mL, or ISUP 1 with PSA 10 to 20; unfavorable is ISUP 2 with PSA 10 to 20, or ISUP 3.1
Can Gleason 7 (3+4) be managed with active surveillance?+
In carefully selected cases, yes. The European guideline accepts surveillance for ISUP 2 with low disease extent, such as less than 10% pattern 4 and a PSA below 10 ng/mL, accepting a higher risk of metastasis. ISUP 3 and tumors with cribriform or intraductal patterns are excluded.2 I personally do not recommend active surveillance for intermediate risk, including favorable intermediate risk.
For intermediate-risk cancer, is surgery or radiotherapy better?+
The European guideline accepts both. Radical prostatectomy is offered to men with a life expectancy above 10 years, and radiotherapy is combined with 4 to 6 months of hormone therapy.2 In the ProtecT trial, at 15 years, cancer death was low and similar with surgery and with radiotherapy.6 The choice depends on the tumor, your age, your health and what you want to preserve.
Does surgery improve survival in intermediate-risk cancer?+
In the Scandinavian SPCG-4 trial, surgery reduced cancer death compared with observation, with 2.9 years of life gained on average.7 In the US PIVOT trial, surgery may have reduced overall mortality in men with intermediate-risk disease, in a subgroup analysis.8
How long can I wait to have surgery?+
In a review of 19 studies, waiting around 3 months generally did not worsen outcomes in intermediate- and high-risk disease.10 In my practice, when I recommend surgery, I advise operating as soon as possible, without hormone therapy while the patient waits, because it is not indicated before prostatectomy.2
Will my lymph nodes need to be removed?+
Not always. The chance that the cancer has reached the lymph nodes is estimated with nomograms.2 I use the 2019 Briganti nomogram, with a 7% cutoff, for men who had an MRI-guided biopsy.11 When I remove the lymph nodes, the dissection is always extended.
Who operates on intermediate-risk prostate cancer in São Paulo?+
I do. I am a urologist and robotic surgeon in São Paulo, Brazil, CRM-SP 157.598 and RQE 70.275, with a PhD from the University of São Paulo Medical School and more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. I have performed robotic radical prostatectomy since 2020 and preserve the erection nerves whenever possible. The first consultation can be online, in English.
References
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: classification and staging systems. European Association of Urology; 2026. EAU
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
- Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64(6):895-902. PubMed
- Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(3):140-150. PubMed
- Musunuru HB, Yamamoto T, Klotz L, et al. Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. J Urol. 2016;196(6):1651-1658. PubMed
- Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388(17):1547-1558. PubMed
- Bill-Axelson A, Holmberg L, Garmo H, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018;379(24):2319-2329. PubMed
- Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377(2):132-142. PubMed
- Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107-118. PubMed
- Laukhtina E, Sari Motlagh R, Mori K, et al. Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. World J Urol. 2021;39(11):4085-4099. PubMed
- Gandaglia G, Ploussard G, Valerio M, et al. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. Eur Urol. 2019;75(3):506-514. PubMed
- Nahas WC, Rodrigues GJ, Rodrigues Gonçalves FA, et al. Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial. J Urol. 2024;212(1):32-40. PubMed
- Suartz CV, Costa MSS, Matalani CFA, et al. Comparative functional, perioperative and oncological outcomes of robot-assisted and open radical prostatectomy: a systematic review and meta-analysis. Int Urol Nephrol. 2026;58(11):4575-4593. PubMed
- Haney CM, Kowalewski KF, Westhoff N, et al. Robot-assisted Versus Conventional Laparoscopic Radical Prostatectomy: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Eur Urol Focus. 2023;9(6):930-937. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
